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Background: A rapid liquid chromatography–tandem mass spectrometric (LC–MS/MS) method was devel-
oped and validated for the quantiﬁcation of reactive oxygen species (ROS) derived free oxysterols and cho-
lesterol in human plasma and atherosclerotic plaque.
Method: In vitro autoxidation of cholesterol during sample pretreatmentwas avoided by applying only one protein
precipitation and re-concentration step using 80 μl plasma. For preparation of 10 mg atherosclerotic plaques an ad-
ditional liquid–liquid extractionwas included. Free 7-keto-, 7-α/ß-hydroxy-, 5,6-α-epoxy-, 5,6-β-epoxycholesterol,
cholestane-3ß,5α,6ß-triol and cholesterol were separated within 7 min on a monolithic column. An API 4000 tan-
demmass spectrometer was applied in positive ionization mode using atmospheric pressure chemical ionization.
Results: The detection limit was 0.1 ng/ml and the linearity ranged from 0.5 to 0.75 to 2000 ng/ml for the
oxysterols and from 50 to 1000 μg/ml for cholesterol. Recovery was between 80.9 and 107.9%. Between-run im-
precision ranged from 7.9 to 11.7%. Analysis of plasma samples from additional 50 middle-aged volunteers re-
vealed a large inter-individual variability (e.g. 7-ketocholesterol 2.63-30.47 ng/ml). Oxysterol concentrations
normalized to cholesterol were about 43 times higher in carotid plaque compared to plasma (n = 5).
Conclusion: This rapid LC–MS/MS method enables reliable quantiﬁcation focused on especially ROS-derived
oxysterols in human plasma and atherosclerotic plaque samples under high-throughput conditions.© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.tandem mass spectrometry;
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Analysis of oxysterols formed via reactive oxygen species (ROS) is of
increasing interest for studying oxidative stress associated diseases
such as atherosclerosis [1,2]. Notably, 7-ketocholesterol, 7-α- and
7-β-hydroxycholesterol, 5,6-α-epoxycholesterol, 5,6-β-epoxycholesterol,
and cholestane-3ß,5α,6ß-triol have been shown to have cytotoxic prop-
erties and inﬂammatory effects in vitro [3–6]. Among these analytes
7-α-hydroxycholesterol is known to be formed both enzymatically and
autoxidatively [7]. 7-ketocholesterol and 7-β-hydroxycholesterol were
identiﬁed in atherosclerotic plaques that have been linked to the initiation
andprogression of atherosclerosis [1,2]. Oxysterols are transported as free
and esteriﬁed form in lipoproteins. In particular the free oxysterols seem
to get high importance as active metabolites regulating cholesterol bio-
synthesis, fatty acid synthesis, LDL receptor expression and cholesterol ef-
ﬂux [8–10]. The analysis of oxysterols is challenging due to their very low
physiological concentrations, structural similarity, and the excess of cho-
lesterol. Gas chromatography coupled to mass spectrometry (GC–MS) is
widely used for oxysterol analysis in plasma and atherosclerotic plaques
[1,2,11,12]. Sample pretreatment includes hydrolysis of esteriﬁed
oxysterols, separation from cholesterol, derivatization and liquid–liquid
extraction (LLE) [13–18]. In recent applications, LC–MS/MS was applied license.
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[19–23].
The susceptibility of cholesterol to in vitro autoxidation during
sample pretreatment and storage plays an important role in oxysterol
analysis [24]. It has been already discussed that some of the previously
measured oxysterols like 7-β-hydroxycholesterol, 7-ketocholesterol,
cholestane-3β,5α,6β-triol and 5,6-epoxycholesterols may be only the
results of in vitro oxidation artifacts [25,26].
The aim of our study was the development of a single-step sample
pretreatment protocol avoiding in vitro cholesterol autoxidation in
combination with a rapid LC–MS/MS method for the simultaneous
analysis of free oxysterols and cholesterol in human plasma and ath-
erosclerotic plaque.
2. Materials and methods
2.1. Materials
Sterol standards were purchased from Steraloids (Newport, Rhode
Island, USA), Euriso-Top, (Saarbrücken, Germany) and Avanti Polar
Lipids (Alabama, USA) (see supplement Table 1). Methanol, acetoni-
trile and isopropanol (ULC-MS grade) were used from Biosolve
(Valkenswaard, Netherlands). Water was puriﬁed using Nano Pure
technology form Thermo Scientiﬁc (Waltham, USA). Butylated hy-
droxytoluene (BHT), sodium hydroxide (NaOH), hydrochloric acid
(HCL) was purchased from Sigma-Aldrich (Munich, Germany). Ethanol,
n-hexane (both LC grade) and sodium sulfate (Na2SO4) was obtained
from Merck KGaA (Darmstadt, Germany). EDTA-K3 containing tubes
and polypropylene tubes were purchased from Sarstedt (Nümbrecht,
Germany), glass vials from Wicom (Heppenheim, Germany) and
96-well plates from Nunc™, Thermo Fisher Scientiﬁc (Karlsruhe,
Germany). Ultrasonic homogenizer UP 100H was purchased from
Dr. Hielscher GmbH (Teltow, Germany). Mikro-Dismembrator S was
from Sartorius AG (Göttingen, Germany).
2.2. Standards and solutions
Stock solution containing oxysterols (each 1 mg/ml in methanol)
and cholesterol (10 mg/ml in isopropanol) were prepared. Calibration
standards with oxysterol concentrations of 0.5, 0.75, 2, 5, 25, 100 and
500 ng/ml were prepared by diluting the stock solutions with metha-
nol. For cholesterol, four calibrators (0.05, 0.1, 0.5, 1.0 mg/ml) were
used. Isotope labeled standards for each oxysterol were reconstituted
in methanol to a concentration of 1 mg/ml. All solutions included
0.05% (v/v) BHT to avoid autoxidation.
Pool plasma at ﬁve different concentration levels: native quality
control (NQC), low concentrated quality control (LQC, spiked with
5 ng/ml oxysterol mix), medium concentrated quality control (MQC,
spiked with 10 ng/ml oxysterol mix), high concentrated quality control
(HQC, spiked with 20 ng/ml oxysterol mix), and pathological concen-
trated quality control (PQC, spiked with 75 ng/ml oxysterol mix) were
prepared as quality control. Standards, calibrators and quality controls
(QC) were aliquoted and stored at−80 °C until analysis.
2.3. Sample collection
EDTA-plasma from 50 (28 male/22 female) fasting healthy volun-
teers aswell as EDTA-plasma and carotid plaques (n = 5) frompatients
undergoing carotid endarterectomy (CEA) were collected. Carotid
plaques were separated from the surgical specimen under a stereomi-
croscope, split into tissue sample aliquots, and stored in liquid nitrogen
until further preparation.
The study was approved by the ethic committee of the University of
Leipzig 148-2005 and 082-10-190-42010. Each participant provided
written informed consent. Plasma and plaque samples were immedi-
ately frozen after centrifugation at 3220 ×g for 10 min and stored inpolypropylene cryotubes at −80 °C until analysis and thawed only
once.
2.4. Sample preparation
80 μl of calibrator, QC, blank (methanol) or plasma sample were
added to 1440 μl methanol/isopropanol 1:1 (v/v), containing the
oxysterol internal standard mixture (each oxysterol c = 5 ng/ml) and
CH-2H7 (c = 200 ng/ml). Samples were mixed thoroughly for 1 min
and centrifuged for 10 min at 12500 ×g. Supernatants were transferred
into glass vials and evaporated to dryness at room temperature under a
stream of nitrogen. At−80 °C stored extracts were reconstituted with
80 μl methanol/water 3:1 (v/v), transferred into 96-well plates and
centrifuged prior to analysis for 5 min at 3220 ×g.
The plaque extraction protocol was optimized using a single
aliquoted plaque (10 mg aliquots). Plaque extraction was performed
for 1 h at 4 °C employing a vortex mixer [27]. Efﬁciency of cholesterol
extraction from plaque was compared for direct solvent extraction
and solvent extraction after plaque homogenization for 0.5, 1, 2 h incu-
bation time. Cholesterol autoxidation was investigated for a cholesterol
solution (c = 500 μg/mL) following the same experimental conditions.
The following solvent mixtures were compared: n-hexane/isopropanol
(3:2, v/v) and acetonitrile/methanol (1:1, v/v), containing 0.01% (v/v)
BHT, respectively [28,29]. Samples were homogenized for 1 min using
an ultrasonic homogenizer or a mikro-dismembrator. After plaque ex-
traction for 1 h with 1200 μl acetonitrile/methanol, the plaque extracts
were directly evaporated after centrifugation for 10 min at 1000 ×g
(4 °C). For plaque extraction with 1200 μl n-hexane/isopropanol, 50 μl
water was added to each plaque sample. After extraction, 300 μl of
0.47 mol/l aqueous Na2SO4 solution was added, mixed thoroughly for
5 min, mixed for 20 min and centrifuged for 10 min at 1000 ×g
(4 °C). The organic phase was evaporated. All dried plaque extracts
were stored at−80 °C. Before LC–MS/MS analysis, the plaque extracts
were reconstituted in 200 μl acetonitrile/methanol (1:1, v/v) and fur-
ther processed according to the described plasma protocol. The plaque
extracts were ﬁnally dissolved in methanol/water (3:1, v/v).
2.5. Chromatography and mass spectrometry
A PE binary micro pump system, series 200 autosampler, a column
oven with a ten-port switching valve (Perkin-Elmer, Rotgau-Jügesheim,
Germany) and an API 4000 triple quadrupole mass spectrometer with
APCI (AB SCIEX, Toronto, Canada) was used. Oxysterols were analyzed
in positive ion mode and multiple reaction monitoring (MRM) (mass
transitions see supplement Table 2). APCI-source parameters were as
follows: source temperature 500 °C, nebulizer current 3, curtain gas
25 psi, gas 1 25 psi and collision induced dissociation (CID) 5.
A Chromolith SpeedRod RP-18e monolithic column (50 × 4.6 mm)
(Merck KGaA, Darmstadt, Germany) was applied. The ﬂow rate was
1 ml/min with solvent A methanol/water (3:1, v/v) and solvent B
100% isopropanol. The gradient elution was as follows: 0–0.5 min 40%
B, 0.5–3.5 min 40 to 70% B, 3.5-6.5 min 100% B, 6.5-7.0 min 40% B. Dur-
ing theﬁrst 0.5 min after sample injection, the eluentwas switched by a
valve to the waste to avoid source contamination from plasma matrix
components.
2.6. Method evaluation
For investigation of in vitro oxidation processes plasma and meth-
anol were spiked with isotope labeled cholesterol (c = 500 μg/ml)
and processed according to the sample preparation protocols.
Matrix effects on oxysterol ionization were evaluated for each
oxysterol (c = 1 μg/ml) by post-column infusion experiments by direct
infusionwith aﬂow rate of 0.01 mL/min to aHPLCﬂow rate of 1 mL/min
and 10-fold injection of a plasma sample. Inﬂuence of excess cholesterol
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oxysterol standard mix (c = 20 ng/ml).
The limit of detection (LOD) was calculated from methanolic
standard solutions after the described sample preparation using a
signal-to-noise (s/n) ratio of 3. The lower and upper limits of quantiﬁca-
tion (LOQ) are stated as the concentration levels meeting the criteria of
a coefﬁcient of variation below 20%. Linearity of the oxysterols was test-
ed up to a concentration of 2000 ng/ml, and for cholesterol in a range
from 50 to 1000 μg/ml.
The accuracy of the method was assessed by recovery studies. Pool
serumwas spiked with standard solutions at appropriate concentration
levels (range 5–75 ng/mL). The within-run and between-run impreci-
sion was determined by preparing and analyzing each quality control
10 times per run and on 10 consecutive working days.
Stability of methanolic standard solutions (oxysterol standard
mixture c = 10 ng/ml) and native and spiked plasma samples
(c = 10 ng/ml) were investigated for three freeze–thaw cycles and
for storage at −80 °C up to 12 weeks with and without addition of
50 μg BHT/ml sample, respectively.3. Results
3.1. Sample pretreatment
Our established serum pretreatment protocol for plant sterol was
modiﬁed for oxysterol analysis [29]. Protein precipitation was
performed by diluting 80 μl of human plasma with 1440 μl methanol/
isopropanol, (1:1, v/v) following evaporation. In vitro formation of
oxysterols derived from isotopic labeled cholesterol was observed
only inmethanolic solutions, but not during plasma sample preparation
(supplement Fig. 1.). In methanolic solutions oxysterol concentrations
decreased during storage time and freeze–thaw cycles without BHT
addition (data not shown). Thus, all methanolic oxysterol standard so-
lutions were treated with 0.05% (v/v) BHT to prevent in vitro autoxida-
tion. BHT addition to plasma did not enhance the stability of oxysterols
in freeze–thaw cycles and storage at−80 °C (data not shown).In
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Fig. 1. LC–MS/MS analysis of a human spiked plasma sample (c = 5 ng/ml) and of an extr
formed oxysterols, (2) cholestane-3ß,5α,6ß-triol, (3) 7-α/ß-hydroxycholesterol, (4) 5,6-ß-
m/z 369/287 (7) cholesterol, (8) sterol ester fraction.For plaque extraction aprevious homogenizationwas omitted tomin-
imize material loss and to prevent autoxidation of cholesterol. The best
extraction yield was obtained by direct incubation and mixing of 10 mg
plaque for 1 h at 4 °C in 1200 μl n-hexane/isopropanol (3:2, v/v) follow-
ed by LLE (supplement Fig 2. and 3.). In vitro formation of cholesterol ox-
idation products did not occur during plaque sample pretreatment by
adding BHT.3.2. Chromatography and mass spectrometry
The monolithic column was chosen due to the efﬁcient chromato-
graphic separation of the isomeric oxysterols 5,6-α-EC/5,6-β-EC and
7-OHC, Triol with MRM 385.3/367.3. The stereoisomers 7-α-OHC and
7-β-OHC could not be separated under the chosen chromatographic
conditions and were indicated in the following as a sum parameter
7-α/β-OHC. An analytical run time of 3 minwas needed for the separa-
tion of 5,6-β-EC, 5,6-α-EC, Triol, 7-α/β-OHC, 7-KC and cholesterol.
Enzymatically formed oxysterols (20-α-OHC, 22-R-OHC, 22-S-OHC,
24-S-OHC, (25R)-27-OHC) were partially separated at a retention
time between 1.2 and 1.4 min. In the end, a total run-time of 7.0 min
was needed for the elution of the free oxysterols, cholesterol and the
sterol ester fractions from plasma and plaque following column
re-equilibration (Fig. 1). Mainly [M + H-H2O]+ ions (for 7-α/β-OHC,
5,6-β-EC, 5,6-α-EC), [M + H-2H2O]+ ions (for Triol), and [M + H]+
ions (for 7-KC) were formed under the optimized conditions using
APCI [30,31].
Inﬂuence of plasma matrix components was investigated by a post
column infusion experiment. No signal suppression or signal enhance-
ment was observed in the oxysterol retention time ranging between
1.5 to 3.0 min (supplement Fig. 4). In addition, peak area ratios of ana-
lyte to internal standard are comparable for spiked plasma and standard
solutions for the sum parameter 7α/β-OHC. In the range from 100 to
1000 μg/ml, excess of cholesterol did not inﬂuence the quantiﬁcation
of 7-α/β-OHC, 7-KC, 5,6-β-EC and Triol, only for 5,6-α-EC a concentra-
tion increase up to 16% was observed at cholesterol concentrations at
1000 mg/ml.0.0
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acted atherosclerotic plaque sample, mass transitions: m/z 385/367 (1) enzymatically
epoxycholesterol, (5) 5,6-α-epoxycholesterol, m/z 401/383 (6) 7-ketocholesterol, and
Table 1
Recovery for four spiked plasma levels with the corresponding coefﬁcient of variation (CV) (n = 10).
Oxysterol (ng/ml) Initial concentration a Added concentration Final concentration b CV %
n = 10
Difference
b − a
Recovery rate %
7-ketocholesterol 2.7 5 7.4 6.3 4.7 103.9
2.7 10 11.9 6.6 9.3 92.8
2.6 20 22.8 2.2 20.2 101.0
2.6 75 81.7 3.9 79.1 105.5
7-α/β-hydroxycholesterol 1.8 5 6.7 4.5 4.9 107.9
1.8 10 11.6 2.4 9.7 97.4
1.8 20 23.1 0.9 21.3 106.5
1.8 75 82.5 3.3 80.7 107.6
5,6-α-epoxycholesterol nd 5 4.3 9.3 4.3 94.2
nd 10 8.5 4.3 8.5 85.0
nd 20 17.1 0.4 17.1 85.5
nd 75 70.4 2.3 70.4 93.9
5,6-β-epoxycholesterol 1.1 5 4.8 10.9 3.7 81.3
1.1 10 9.2 5.1 8.1 80.9
2.2 20 19.5 0.8 17.3 86.5
2.2 75 74.7 2.9 72.5 96.7
Cholestane-3ß,5α,6ß-triol nd 5 4.4 5.5 4.4 96.5
nd 10 8.2 5.2 8.2 81.6
nd 20 17.0 1.2 17.0 85.0
nd 75 72.0 3.0 72.0 96.0
nd = not detectable.
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The LOD was 0.1 ng/ml for all oxysterols and the LLOQ were
0.5 ng/ml for 7-α/β-OHC, 0.75 ng/ml for 7-KC, 5,6-α-EC, 5,6-β-EC,
Triol as well as 50 μg/ml for cholesterol [19,23]. The standard curves
were linear between 0.5 and 2000 ng/ml for oxysterols and 50–
1000 μg/ml for cholesterol (see supplement Table 3). A chromato-
gram of the blank sample and chromatograms with analyte concen-
trations at the LLOQ are shown in supplement Fig. 5.Table 2
Within- and between-day variability of native plasma and four spiked plasma levels
(n = 10).
Analyte Concentration
(ng/ml)
Within-day CV
(n = 10)
Between-day CV
(n = 10)
Mean
(ng/ml)
CV,
%
Mean
(ng/ml)
CV,
%
7-ketocholesterol Native 2.7 15.6 2.6 24.7
5 7.4 4.2 7.3 10.6
10 11.9 5.4 12.4 6.3
20 22.8 9.5 24.6 7.4
75 81.7 4.7 87.3 5.5
7-α/β-hydroxycholesterol Native 1.9 11.3 1.8 9.4
5 6.7 3.4 6.9 7.9
10 11.6 2.1 12.4 8.8
20 23.1 4.0 20.4 4.7
75 82.5 4.0 75.7 4.7
5,6-α-epoxycholesterol Native b0.75 b0.75
5 4.3 9.8 4.6 9.7
10 8.5 4.5 10.0 7.9
20 17.1 2.5 19.0 6.7
75 70.4 3.3 71.9 4.5
5,6-β-epoxycholesterol Native 1.6 21.8 2.2 26.0
5 4.8 8.9 6.2 11.3
10 9.2 4.7 11.3 8.3
20 19.5 4.0 19.6 7.7
75 74.7 3.9 71.6 5.7
Cholestane-3ß,5α,6ß-triol Native b0.75 b0.75
5 4.4 5.8 4.3 11.7
10 8.2 5.5 9.1 10.2
20 17.0 6.8 15.5 7.2
75 72.0 4.2 62.0 6.5
Cholesterol Native 467 μg/ml 4.7 472.9 μg/ml 7.3Accuracy, assessed by standard addition experiments, ranged be-
tween 80.9 and 107.9% (Table 1). Thewithin-run imprecision ranged be-
tween 11.3 and 21.8% for native plasma specimens, and between 3.4 and
9.8% for the spiked quality control samples. The between-run impreci-
sion was up to 26% in native plasma and between 7.9 and 11.7% for
spiked plasma samples. Precision data are summarized in Table 2.3.4. Oxysterols in human plasma and atherosclerotic plaque
The free oxysterol plasma concentrations of 50 middle-aged vol-
unteers are summarized in Table 3. The plasma concentrations for
free cholesterol were 471 ± 104 μg/ml (mean ± SD). 7-α/β-OHC
was signiﬁcantly correlated with cholesterol (r = 0.687, p = 0.009).
The oxysterol distribution in plasma was 7-KC (57.0%) N 7-α/
β-OHC (20.7%) N 5,6-β-EC (11.7%) N Triol (10.5%) N 5,6-α-EC
(bLLOQ) (Table 4). In contrast the oxysterol distribution in plaque
differed: 7-KC (54.8%) N Triol (13.5%) N 7-α/β-OHC (11.6%) N
5,6-β-EC (10.1%) N 5,6-α-EC (10.0%). The concentrations of oxysterols
normalized to free cholesterol, analyzed in the 5 human plaque samples
are shown in Table 4. The oxysterol concentrations for plaque and the
corresponding plasma samples normalized to total cholesterol are listed
in supplement Table 4.Table 3
Free oxysterol concentrations in EDTA-plasma samples from 50 volunteers (male = 28,
female = 22).
Analyte Human plasma, n = 50
Absolute
concentration
Relative concentration
Median
(ng/ml)
2.5–97.5
percentile
Median
(ng/mg CH)
2.5–97.5
percentile
Na
7-ketocholesterol 6.19 2.63–30.47 13.08 7.26–51.62 50
7-α/β-hydroxycholesterol 3.50 1.17–20.64 8.18 2.81–45.69 50
5,6-α-epoxycholesterol 1.34 0.75–2.62 3.04 1.21–5.48 19
5,6-β-epoxycholesterol 6.02 2.68–13.03 12.89 6.40–28.31 50
Cholestane-3ß,5α,6ß-triol 1.42 0.76–8.05 3.07 1.79–11.67 38
a Number of plasma samples with quantiﬁable oxysterol concentrations.
Table 4
Free oxysterol concentrations adjusted to free cholesterol in atherosclerotic plaque and corresponding plasma samples (n = 5).
Analyte
(ng/mg free cholesterol)
Atherosclerotic plaque Human plasma
Median Range Median Range
7-ketocholesterol/cholesterol 607.1 205.9–1407.6 14.6 5.9–29.7
7-α/β-hydroxycholesterol/cholesterol 128.0 75.6–216.8 5.3 3.1–13.7
5,6-α-epoxycholesterol/cholesterol 110.7 34.4–165.4 nd
5,6-β-epoxycholesterol/cholesterol 112.2 95.5–334.2 3.0 1.6–7.6
Cholestane-3ß,5α,6ß-triol/cholesterol 149.4 57.7–340.8 2.7 1.8–5.2
nd = not detectable.
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The main challenge in oxysterol analysis is the excess of cholesterol
and its potential to in vitro oxidation. Previous described analytical
methods include LLE, SPE saponiﬁcation and derivatization prior GC–
MS or LC–MS/MS analysis. BHT is often added to avoid these effects but
it has already been discussed that some of the previously measured
oxysterols are only products of in vitro oxidation [25,26].
We developed a one step sample pretreatment protocol including
protein precipitation for plasma and a simple extraction procedure for
atherosclerotic plaques for oxysterol analysis. Plasma volume could be
reduced to 80 μl and the required plaque amount was only 10 mg for
oxysterol analysis [21,22]. Former described GC–MS application needed
70–240 mg plaque per analysis [1]. Applying this pretreatment protocol,
in vitro formation of oxysterols derived from isotopic labeled cholesterol
in plasma was not observed. Epoxycholesterol formation which was de-
scribed during GC–MS sample pretreatment was not noticed [32]. The
conversion of 5,6-EC to Triol by non-physiological temperatures and
the use of acidic medium in the sample preparation could be avoided
[33]. However, a three-fold increase of the 5,6-α-EC-2H7 was found in
processing methanolic isotope labeled cholesterol solution without
BHT addition probably due to a lack of antioxidants and stabilizers that
are usually in physiological samples.
An additional important advantage of the developed LC–MS/MS
method is the simultaneous analysis of free oxysterols and free cho-
lesterol in a total run time of 7 min. This enables the normalization
of plaque- and plasma oxysterol concentrations to cholesterol and
therefore allows the comparison of oxysterol concentrations between
blood and plaque as well as between morphologically heterogeneous
plaque samples. However, 7-α- and 7-β-OHC can be analyzed only as
sum parameter which is a limitation of the method. Because 7-α-OHC
can also be derived enzymatically, the 7-hydroxycholesterol signal
can be used only approximately for ROS activity.
The method development was focused on the free oxysterol frac-
tion that represents the likely active form to investigate its effects
on oxidative stress and atherogenic processes [7].
Due to the sensitivity of the developed LC–MS/MS method it can be
used for the determination of free oxysterols in plasma and plaque sam-
ples. By using the sample preparation protocol autoxidation could be
avoided so that the oxysterols present are in very lowphysiological con-
centrations. In this range the variability of free 7-ketocholesterol and
free 5,6-β-epoxycholesterol concentrations were N20%.
The analyzed free oxysterol plasma concentrations of 50middle-aged
volunteers showed as previously described a high inter-individual varia-
tion [19,23,32]. However, 7-KC/CH and 7-α/β-OHC/CH concentrations in
plaque samples were 31 and 45% lower compared to previously used
methods applying more laborious sample pretreatment protocols [1].
Additionally free 5,6-α-EC and free 5,6-β-EC were quantiﬁed with
3–100-fold lower plasma concentrations as described by GC–MS
methods. This may be the effect of the gentle sample pretreatment
avoiding in vitro cholesterol autoxidation [13,14].
In carotid plaque the relative oxysterol concentrations were be-
tween 24- and 55-times higher compared to plasma. Interestingly, in
carotid plaque Triol and 5,6-ECs seem to be more highly concentratedcompared to other ROS-derived oxysterols. However, further investiga-
tions in a larger study cohort have to follow to clarify these ﬁndings.
5. Conclusion
We developed a fast LC–MS/MS method for the simultaneous
quantiﬁcation of ﬁve ROS-derived oxysterols: free 7-KC, 7-α/β-OHC,
5,6-α-EC, 5,6-β-EC, Triol, and free cholesterol in 80 μl human plasma
or 10 mg atherosclerotic plaque. For the ﬁrst time, complex sample
pretreatment protocols of human plasma and extracted plaque sam-
ples could be reduced to a single protein precipitation and concentra-
tion step which avoids in vitro cholesterol autoxidation.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.cca.2013.06.022.
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